SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Goldman Sachs Buy upgrade, citing Palantirs opportunities in sovereign AI and customized software, is a key focus as shares break to fresh highs. Bulls celebrate the momentum and speculate about short-covering, while skeptics warn that the valuation is stretched and the rally could pull back.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs agreement to acquire low-band spectrum for Starlink Mobile has fueled a sharp selloff in T-Mobile and other U.S. wireless carriers, as traders weigh the prospect of a new competitor. The community is divided between viewing the deal as a long-term threat and calling the drop an overreaction, arguing that building a competitive network will take substantial time and infrastructure.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRK is attracting attention amid a rally and renewed focus on Starknets post-quantum security, privacy features and Bitcoin DeFi, including discussion of a quantum-resistant transaction test and strkBTC. Bullish traders see these developments as differentiators, while skeptics continue to point to token unlocks and dilution as potential selling pressure.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladocs weaker quarterly outlook, driven largely by BetterHelps transition from cash-pay customers to insurance, is fueling debate over whether the shift can restore growth. Bears cite declining revenue and lost confidence in management, while bulls argue insurance demand is strong but provider capacity and execution will take time to catch up.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

SpaceXs agreement to acquire low-band spectrum for its Starlink Mobile ambitions has fueled a sharp selloff in AT&T shares. Traders debate whether it signals a meaningful long-term competitive threat or an overreaction, arguing that a competing network would take substantial time and investment; many are buying the dip and pointing to AT&Ts established business and dividend.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the following business segments: Consumer and Business. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

SpaceXs agreement to acquire low-band spectrum for Starlink Mobile has fueled concerns that it could eventually compete with Verizon and other wireless carriers, weighing on VZ shares. Traders are split between seeing a meaningful long-term threat and calling the selloff overdone given the time, investment, and infrastructure needed to build a competing network; some are buying the dip for Verizons dividend.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention centers on TG Therapeutics scheduled MSToronto presentations, especially initial Phase 1 azer-cel findings in progressive MS and BRIUMVI trial data. Traders see the late-breaking presentation as encouraging but not proof of efficacy, while upcoming BRIUMVI subcutaneous Phase 3 results also support bullish interest; buyout and short-squeeze claims remain speculation amid volatile trading.

Fortinet, Inc. provides cybersecurity solutions to a variety of businesses, such as enterprises, communication service providers, government organizations, and small to medium-sized businesses. Its product portfolio includes network security, secure access service edge, enterprise networking, security operations, application security, and operational technology. The company was founded by Ken Xie and Michael Xie in November 2000 and is headquartered in Sunnyvale, CA.

Fortinet Inc

Fortinet is drawing attention for its breakout to fresh highs amid strength across cybersecurity stocks, as traders see rising AI-related security risks as a sector tailwind. Bulls point to strong momentum, while skeptics warn that stretched valuations and light trading volume could leave the rally vulnerable to a pullback.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET is drawing attention around managements updates on optical-engine production, customer qualification, manufacturing yields and planned capacity expansion. Bulls view the reported progress as evidence the company is moving toward commercialization, while skeptics remain frustrated by limited customer and order details and question whether the ramp will translate into meaningful revenue.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Attention centers on Himaxs upcoming quarterly results and whether revenue growth and margins can support its valuation, alongside longer-term hopes for CPO and automotive demand. Traders are split between buying the pullback and concerns about semiconductor weakness and rumored CPO competition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Annovis Bio (ANVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Annovis Bio, Inc. (NYSE:ANVS) Sees Significant Increase in Short Interest

Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totaling 4,760,673 shares, a growth of...

Traders Buy Large Volume of Annovis Bio Call Options (NYSE:ANVS)

Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) was the target of unusually large options trading activity on Thursday. Traders bought 3,361 call options on the stock. This represents an increase of...

Insider Buying: Annovis Bio (NYSE:ANVS) Director Acquires 713,800 Shares of Stock

Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) Director Michael Hoffman bought 713,800 shares of the business's stock in a transaction dated Thursday, April 2nd. The stock was acquired at an average...

Annovis Bio (NYSE:ANVS) Releases Earnings Results, Misses Expectations By $0.08 EPS

Annovis Bio (NYSE:ANVS - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of...

Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Friday

Annovis Bio (NYSE:ANVS) will be releasing its Q4 2025 earnings before the market opens on Friday, March 20. (View Earnings Report at...

Annovis Bio (NYSE:ANVS) Stock Price Down 8.5% - What's Next?

Annovis Bio (NYSE:ANVS) Stock Price Down 8.5% - Here's What Happened...

Annovis Bio (NYSE:ANVS) Shares Down 1% - Here's Why

Annovis Bio (NYSE:ANVS) Shares Down 1% - Should You Sell...

Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of "Hold" from Analysts

Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. One...

Annovis Bio, Inc. (NYSE:ANVS) Given Consensus Rating of "Hold" by Analysts

Shares of Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) have been assigned an average recommendation of "Hold" from the five brokerages that are currently covering the firm, MarketBeat Ratings...

Reported GAAP EPS of -$0.40 down -25.00% YoY

Annovis Bio, Inc. faces substantial doubt regarding its ability to continue as a going concern, driven by increasing net losses and the requirement for additional capital to fund future operations.

Annovis Bio, Inc. achieved full enrollment for its pivotal Phase 3 Alzheimer's study and secured FDA alignment on a regulatory path for its lead drug candidate, buntanetap, across multiple indications.

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. The company's product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. Annovis Bio was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

Annovis Bio Inc

Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia

Equity

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$1.21
Prev Close	$1.17
Open	$1.17
Dividend Yield	0.00%
50-Day Moving Average	$1.50
Beta	1.70
Avg. Volume	1.42M
PE Ratio	-0.68

52-Week High	$5.50
52-Week Low	$1.04
Market Capitalization	$49.93M
EPS (Annual)	-$1.40
Price to Book	-12.12
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ANVS Fundamentals